PipISB is a drug used in scientific research which acts as a potent and selective
inverse agonist of the
cannabinoid receptorCB1. It is highly selective for the CB1 receptor over CB2, with a
Kd at CB1 of 1.5nM vs over 7000nM at CB2, has good
blood–brain barrier penetration, and can be conveniently
radiolabelled with either 11C or 18F, making it useful for mapping the distribution of CB1 receptors in the brain.[1][2]
References
^Donohue SR, Halldin C, Schou M, Hong J, Phebus L, Chernet E, et al. (2008). "Radiolabeling of a high potency cannabinoid subtype-1 receptor inverse agonist, N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl-indole-1-sulfonyl)benzamide (PipISB), with carbon-11 or fluorine-18". Journal of Labelled Compounds and Radiopharmaceuticals. 51 (3): 146.
doi:
10.1002/jlcr.1491.